Neil Dey

Locus Biosciences is a clinical-stage biotechnology company developing precision antibacterial therapies to address the global challenge of antibiotic resistance. The company utilizes its proprietary crPhage platform, which combines the natural targeting ability of bacteriophages with the precision of CRISPR-Cas3 technology to selectively destroy the DNA of specific bacterial pathogens. Their lead program, LBP-EC01, is currently in Phase 2 clinical trials for the treatment of urinary tract infections caused by Escherichia coli. Beyond infectious diseases, Locus is exploring applications of its platform in microbiome-related conditions such as inflammatory bowel disease. By engineering phages to deliver a lethal CRISPR payload, the company aims to provide a highly targeted alternative to broad-spectrum antibiotics.